Wockhardt

Wockhardt Ltd is a research and technology oriented pharmaceutical company focused on the R&D of therapeutics in anti-infectives, sepsis, pain & inflammation, psychiatry, medical nutrition and biotechnology segments.In July 2018, the company had established its manufacturing facility in Middle East.In July 2013, the MHRA issued a precautionary recall of prescription products after manufacturing deficiencies were identified at the company's facility in Waluj, India during an inspection in March 2013.By May 2013, the company had manufacturing facilities in India, the US, the UK and Ireland.In September 2006, Wockhardt signed an agreement to build a pharmaceutical and biopharmaceutical manufacturing and research facility at a 107-hectare site in Aurangabad, India. The facility would employ 2000 people.In October 2004, Wockhardt sold its plant at Luton, UK to Bristol Laboratories Corp. Products formerly manufactured at Luton would now be made at a plant at Wrexham in Wal